News Sentiment

CODX sentiment intelligence

Co-Diagnostics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 43 Balanced news tone 35 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 2.61 Week of 10 Jul 2026
Weighted tone 43/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 24

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-12.7% over one week, -39.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

CODX Stock Price, Quote & Chart

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -12.7% Price reacting lower
Trend fit Trend inactive -39.2% over four weeks
Fair value -88.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 4
Neutral 21
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 24
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
StockStory 3
PR Newswire 3
Barron's 2
Stocktwits 2
The Globe and Mail 2
Investing.com 2
ChartMill 1

Event Lens

What the news is about

Classified themes
Earnings 16
Market update 16
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 35
Morningstar Direct company coverage

Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai

Co-Diagnostics, Inc. announced its participation in the World Health Expo Labs Dubai from February 10-13, 2026, where it will showcase its Co-Dx™ PCR platform. This exhibition follows the formation of its joint venture, CoMira Diagnostics, aimed at localizing manufacturing and di

Tone
Positive 75/100
Event
Market update
Published
09 Feb 2026 14:00
Source
Morningstar
PR Newswire Direct company coverage

Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform

Co-Diagnostics, Inc.'s joint venture, CoSara Diagnostics Pvt. Ltd., has achieved ISO 13485:2016 certification for its manufacturing facility in Vadodara, India. This certification is a crucial step for securing regulatory clearance for their upcoming PCR platform and other medica

Tone
Positive 73/100
Event
Regulatory and legal
Published
04 Feb 2026 09:00
Source
PR Newswire
AD HOC NEWS Direct company coverage

Co-Diagnostics Shares Transition to Over-the-Counter Trading

Co-Diagnostics Inc. (CODX) has moved from the Nasdaq Capital Market to over-the-counter trading due to its inability to maintain the minimum share price requirement. Despite a 1-for-30 reverse stock split, the company failed to sustain a $1.00 closing bid price. This delisting fo

Tone
Negative 28/100
Event
Market update
Published
18 Jan 2026 06:28
Source
AD HOC NEWS
Chartmill Direct company coverage

CODX Stock Price, Forecast & Analysis | CO-DIAGNOSTICS INC (NASDAQ:CODX)

This article provides an in-depth analysis of CO-DIAGNOSTICS INC (CODX) stock, including its current price, historical performance, and key statistics. It also features technical and fundamental analysis, analyst ratings, and financial highlights, concluding with a company profil

Tone
Negative 19/100
Event
Guidance
Published
15 Jan 2026 04:57
Source
Chartmill
The Globe and Mail Direct company coverage

Co-Diagnostics Faces Nasdaq Delisting After Bid Price Noncompliance

Co-Diagnostics (CODX) is facing delisting from the Nasdaq Capital Market due to non-compliance with the minimum $1.00 bid price requirement. Trading in its securities is suspended from Nasdaq as of January 14, 2026, and will move to the OTC Market. Despite a recent reverse stock

Tone
Neutral 50/100
Event
Market update
Published
14 Jan 2026 21:57
Source
The Globe and Mail
TradingView — Track All Markets Direct company coverage

Co-Diagnostics Received Notice of Delisting

Co-Diagnostics (CODX) received a delisting notice from Nasdaq due to noncompliance with the $1.00 minimum bid price rule. Trading on The Nasdaq Capital Market will be suspended on January 14, 2026, and the stock is expected to move to the OTC Pink Limited Information tier. The co

Tone
Negative 13/100
Event
Market update
Published
13 Jan 2026 17:27
Source
TradingView — Track All Markets
Investing.com Direct company coverage

Co-Diagnostics to be delisted from Nasdaq, trading to move to OTC Market

Co-Diagnostics (NASDAQ: CODX) is facing delisting from the Nasdaq Capital Market due to its failure to meet the minimum bid price requirement. The company's securities will be suspended from Nasdaq trading and will move to the Pink Limited Information tier of the OTC Market. Desp

Tone
Negative 10/100
Event
Market update
Published
13 Jan 2026 17:27
Source
Investing.com
Investing.com South Africa Direct company coverage

Co-Diagnostics announces 1-for-30 reverse stock split By Investing.com

Co-Diagnostics, Inc. (NASDAQ:CODX) will effect a 1-for-30 reverse stock split on January 2, 2026, to meet Nasdaq's minimum bid price requirement. The company's stock has plummeted 69.44% year-to-date, and it reported significant revenue decline in Q3 2025. Despite financial chall

Tone
Negative 30/100
Event
Earnings
Published
12 Jan 2026 17:58
Source
Investing.com South Africa
PR Newswire Direct company coverage

Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

Co-Diagnostics, Inc. announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., is expanding its distributor base in India by participating in regional conferences. CoSara introduced its SARAGENE® diagnostic products and the upcoming Co-Dx™ PCR platform to new custome

Tone
Positive 72/100
Event
Market update
Published
12 Jan 2026 13:58
Source
PR Newswire
The Globe and Mail Direct company coverage

Co-Diagnostics Approves Reverse Stock Split to Maintain Listing

Co-Diagnostics (CODX) has approved a 1-for-30 reverse stock split, effective January 2, 2026, to regain compliance with Nasdaq's minimum bid price requirement. This move is aimed at preserving the company's listing and access to public capital markets. While analysts have a "Hold

Tone
Negative 29/100
Event
Market update
Published
31 Dec 2025 15:09
Source
The Globe and Mail
Market source Direct company coverage

Co-Diagnostics announces 1-for-30 reverse stock split

Co-Diagnostics (CODX) has announced a 1-for-30 reverse stock split of its common stock, effective January 2, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company's stock will continue trading on The Nasdaq Capital Market under the symbol "CODX" on a

Tone
Negative 29/100
Event
Market update
Published
31 Dec 2025 14:09
Source
Market source